Fusion Pharmaceuticals Inc. (FUSN): Price and Financial Metrics

Fusion Pharmaceuticals Inc. (FUSN): $2.40

0.05 (+2.13%)

POWR Rating

Component Grades














  • Sentiment is the dimension where FUSN ranks best; there it ranks ahead of 64.63% of US stocks.
  • FUSN's strongest trending metric is Growth; it's been moving down over the last 56 days.
  • FUSN ranks lowest in Momentum; there it ranks in the 5th percentile.

FUSN Stock Summary

  • With a price/sales ratio of 55.4, FUSION PHARMACEUTICALS INC has a higher such ratio than 96.62% of stocks in our set.
  • With a year-over-year growth in debt of 468.3%, FUSION PHARMACEUTICALS INC's debt growth rate surpasses 96.26% of about US stocks.
  • In terms of volatility of its share price, FUSN is more volatile than 93.85% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to FUSION PHARMACEUTICALS INC are TFFP, FULC, VLN, CDAK, and CLGN.
  • To check out FUSION PHARMACEUTICALS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001805890.

FUSN Valuation Summary

  • FUSN's price/sales ratio is 55.1; this is 1047.92% higher than that of the median Healthcare stock.
  • FUSN's price/earnings ratio has moved up 42.5 over the prior 30 months.

Below are key valuation metrics over time for FUSN.

Stock Date P/S P/B P/E EV/EBIT
FUSN 2022-12-05 55.1 0.6 -1.3 -0.5
FUSN 2022-12-02 53.1 0.6 -1.3 -0.4
FUSN 2022-12-01 53.5 0.6 -1.3 -0.4
FUSN 2022-11-30 53.1 0.6 -1.3 -0.4
FUSN 2022-11-29 50.5 0.5 -1.2 -0.4
FUSN 2022-11-28 49.1 0.5 -1.2 -0.3

FUSN Price Target

For more insight on analysts targets of FUSN, see our FUSN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.20 Average Broker Recommendation 1.3 (Strong Buy)

FUSN Stock Price Chart Interactive Chart >

Price chart for FUSN

FUSN Price/Volume Stats

Current price $2.40 52-week high $8.73
Prev. close $2.35 52-week low $1.98
Day low $2.30 Volume 85,000
Day high $2.52 Avg. volume 58,066
50-day MA $2.40 Dividend yield N/A
200-day MA $3.78 Market Cap 107.43M

Fusion Pharmaceuticals Inc. (FUSN) Company Bio

Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.

FUSN Latest News Stream

Event/Time News Detail
Loading, please wait...

FUSN Latest Social Stream

Loading social stream, please wait...

View Full FUSN Social Stream

Latest FUSN News From Around the Web

Below are the latest news stories about FUSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FUSN as an investment opportunity.

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 13,200 shares of its common stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employe

Yahoo | December 7, 2022

JonesTrading Sticks to Its Buy Rating for Fusion Pharmaceuticals (FUSN)

JonesTrading analyst Justin Walsh maintained a Buy rating on Fusion Pharmaceuticals (FUSN - Research Report) on November 8 and set a price target of $10.00. The company's shares opened today at $2.18.According to TipRanks, Walsh is an analyst with an average return of -31.1% and a 19.05% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fusion Pharmaceuticals with a $10.00 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $8.73 and a one-year low of $1.98.

Austin Angelo on TipRanks | November 10, 2022

Fusion Pharmaceuticals Inc. (FUSN) Reports Q3 Loss, Lags Revenue Estimates

Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of -5.77% and 66.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 8, 2022

Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.

Yahoo | November 8, 2022

Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer.

Yahoo | November 7, 2022

Read More 'FUSN' Stories Here

FUSN Price Returns

1-mo 14.29%
3-mo -7.69%
6-mo -35.14%
1-year -54.80%
3-year N/A
5-year N/A
YTD -42.45%
2021 -64.51%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8407 seconds.